☆ 4.6 Article

Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management

GYNECOLOGIC ONCOLOGY (2023)

期刊

GYNECOLOGIC ONCOLOGY

卷 170, 期 -, 页码 93-101

出版社

ACADEMIC PRESS INC ELSEVIER SCIENCE

DOI: 10.1016/j.ygyno.2022.12.022

关键词

Female germ cell tumor; Survival; International germ cell Cancer collaborative; group riskclassification

类别

Oncology Obstetrics & Gynecology

向作者/读者索取更多资源

Protocol

社区支持

Reagent

社区支持

智能总结 New
摘要

The objective of this study was to validate the modified international male IGCCCG prognostic model in female patients with germ cell tumors (GCTs). The results demonstrated that the modified IGCCCG model accurately assessed the prognostic risk in female GCTs patients and was associated with clinical outcomes.

Objective. We previously developed preoperative and pre-chemotherapy modified versions of the male International Germ Cell Cancer Collaborative Group (IGCCCG) prognostic model and assessed it in female patients with germ cell tumors (GCTs). We sought to validate these modified IGCCCG (mIGCCCG) models in a new cohort. Methods. We queried institutional databases for female patients with GCTs treated at Memorial Sloan Kettering Cancer Center from 1/1/1990-6/1/2020. The mIGCCCG model classifies patients with non-dysgerminomas as good, intermediate, or poor risk based on tumor markers using male IGCCCG cutoffs and absence/presence of non-pulmonary/peritoneal visceral metastasis. In dysgerminomas, good- and intermediate-risk groups are defined by absence/presence of non-pulmonary/peritoneal visceral metastasis. Progression-free survival (PFS) and overall survival (OS) were estimated for each group in the validation and combined original and validation cohorts. Associations between individual clinical factors and outcomes were evaluated. Results. Among 183 female patients with GCTs, clinical characteristics and outcomes were similar between the original (n = 93) and validation (n = 90) cohorts. In multivariable models, higher stage, older age, and non-dysgerminoma histology predicted worse PFS and OS (p < 0.05). Among 162 patients who received chemotherapy, preoperative and pre-chemotherapy mIGCCCG models were significantly associated with PFS and OS (p < 0.001 for all groups). With the preoperative model, 3-year PFS rates were 94%, 76%, and 50% in the good-, intermediate-, and poor-risk patients, respectively; OS rates were 96%, 86%, and 52%, respectively. Even within stage groups, mIGCCCG risk classifications were associated with clinical outcomes.

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

主要评分

4.6

评分不足

次要评分

新颖性

重要性

科学严谨性

评价这篇论文

Outcomes of men with HIV and germ cell cancer: Results from an international collaborative study

Marcus Ulrich Hentrich, Mark Bower, Gedske Daugaard, Annette Dieing, Markus Bickel, Massimiliano Berretta, Florian Lesmeister, Vindi Jurinovic, Albrecht Stoehr, Julia Heinzelbecker, Ivanka Krznaric, Klaus-Peter Dieckmann, Andrea Necchi, Pablo Maroto Rey, Jurgen Kurt Rockstroh, Margarida Brito, David Pfister, Christian Hoffmann

Summary: This study examined the characteristics, treatments, and outcomes of 89 men with HIV-associated germ cell cancer (HIV-GCC) in the era of effective combination antiretroviral therapies. The long-term outcomes of men with HIV-GCC were similar to those reported for men with HIV-negative GCC, suggesting that patients with HIV-GCC should be managed identically to HIV-negative patients.

CANCER (2022)